4.05 Exodus from Academia and the Regretful FDA Approval of Aducanumab with Dr. Ameet Sarpatwari

from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH

Today we are joined by Dr. Ameet Sarpatwari of Harvard Medical School to discuss how so many great minds in oncology are leaving cancer research in academia for industry. We also talk about the evidence (or lack thereof) behind the recent FDA approval of aducanumab to treat Alzheimer's disease. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Episode metadata supplied by the publisher feed · Published Jul 7, 2021

Embed this episode

Attribution link and audio player

Ready to play

4.05 Exodus from Academia and the Regretful FDA Approval of Aducanumab with Dr. Ameet Sarpatwari

0:00 53:16

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 53 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on July 7, 2021.

Can I download this Plenary Session - inactive due to federal service episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!